1. |
Brutsaert DL, Fransen P, Andries LJ, et al. Cardiac endothelium and myocardial function. Cardiovasc Res, 1998, 38(2): 281-290.
|
2. |
Suzuki H, Nakamoto H, Okada H, et al. A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv perit Dial, 2003, 19: 59-66.
|
3. |
Anan F, Takahashi N, Ooie T, et al. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism, 2004, 53(6): 777-781.
|
4. |
Chatterjee K. Primary diastolic heart failure. Am J Geriatr Cardiol, 2002, 11(3): 178-187.
|
5. |
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation, 2002, 105(12): 1503-1508.
|
6. |
Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension, 1999, 34(5): 1112-1116.
|
7. |
Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens, 2002, 11(5): 475-482.
|
8. |
Milionis HJ, Nikas S, Elisaf MS. Effects of losartan/ diuretic combination treatment on serum uric acid levels in hypertensive patients. Am J Caodiol, 2001, 88(9): 1084.??9 劉力生, 龔蘭生. 高血壓. 主編. 北京: 人民衛生出版社, 2003, 15-19; 255-265; 850-852; 878-883.
|
9. |
潘曄生. 血管緊張素受體拮抗對高血壓血管重構的影響. 國外醫學?心血管疾病分冊, 2001, 28(2): 109-110.
|
10. |
劉國仗, 馬文君, 王兵. 高血壓藥物治療的現狀和展望. 中華心血管病雜志, 2003, 31(2): 157-158.
|